Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 5/20 | 0.82 |
| ▸ | CDK2 | P24941 | 5/20 | 0.82 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.82 |
| ▸ | NPC1 | O15118 | 7/20 | 0.81 |
| ▸ | RAB9A | P51151 | 7/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | GRM5 | P41594 | 3/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8141305 | 0.90 | CCNA2 (1.00) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL6341557 | 0.88 | CCNA2 (0.85) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL13777922 | 0.84 | CCNA2 (0.78) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL17627060 | 0.84 | CCNA2 (0.72) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL9132190 | 0.83 | CCNA2 (0.66) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL6339310 | 0.83 | NPC1 (0.66) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL4725840 | 0.81 | CCNA2 (0.73) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL17538513 | 0.77 | CCNA2 (0.71) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL6341559 | 0.77 | CCNA2 (0.62) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL6349668 | 0.77 | CCNA2 (0.62) | CCNA2CDK2CCNA1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | PRNP, APP, MAPT | CCNA2 2618/4885CDK2 2181/4885CCNA1 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.